All In Biotech

Drug Trial Radar · NCT00844298

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Tasigna® (Nilotinib) Plus Multi-Agent Chemotherapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Last checked: Nov 20, 2026Latest source record: Sep 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

91

Actual

Start

Jan 2009

Primary completion

Jun 2012

Study completion Jul 2014

Sponsor

Lead sponsor
Asan Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving nilotinib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving nilotinib together with combination chemotherapy works in treating patients with newly diagnosed acute lymphoblastic leukemia.

Conditions

  • Leukemia

Interventions

  • Nilotinib+mVPDDrug

    1. Induction: * Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3) * Vincristine 2 mg iv push (d1, 8, 15, 22) * Prednisolone 60 mg/m2/day po (d1-28) * Nilotinib 400mg bid/d (d8-) 2. Consolidation A (cycle1) * Daunorubicin 45 mg/m2/day by continuous iv (d1, 2) * Vincristine 2 mg iv (d1, 8) * Prednisolone 60 mg/m2/day po (d1-14) * Nilotinib 400mg bid/d 3. Consolidation B (cycles 2\&4) * Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4) * Etoposide 150 mg/m2/day iv over 3 hours (d1-4) * Nilotinib 400mg bid/d 4. Consolidation C (cycles 3\&5) * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16) * Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses, * Nilotinib 400mg bid/d 5. Maintenance ◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT) 6. Consider alloHCT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction TherapyTime frame: 1 month

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Daegu Fatima Hospital

    Daegu, South Korea

  • Kyungpook National University Hospital

    Daegu, South Korea

  • Yeungnam University Medical Center

    Daegu, South Korea

  • Daegu Catholic University Hospital

    Daegu, South Korea

  • National Cancer Center - Korea

    Goyang, South Korea

  • Chonnam National University Hwasun Hospital

    Jeollanam-do, South Korea

  • Gyeongsang National University Hospital

    Jinju, South Korea

  • Pusan National University Hospital

    Pusan, South Korea

  • Inje University Seoul Paik Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Kyung Hee University Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Asan Medical Center - University of Ulsan College of Medicine

    Seoul, South Korea

  • Konkuk University Medical Center

    Seoul, South Korea

  • Ajou University Hospital

    Suwon, South Korea

  • Ulsan University Hospital

    Ulsan, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.